Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

Launched by M.D. ANDERSON CANCER CENTER · Feb 24, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how repeated MRI scans can help doctors understand changes in tumors during treatment for high-grade glioma, a type of brain cancer. The goal is to see if these additional scans can provide important information that might lead to adjustments in the treatment plan, which includes radiation and chemotherapy. By tracking how the tumor responds to treatment, researchers hope to improve the care patients receive.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of high-grade glioma. They should also be able to undergo an MRI scan with a special dye called gadolinium. Additionally, women who can become pregnant need to confirm they are not pregnant or breastfeeding before joining the study. Participants can expect to have regular MRI scans throughout their treatment, and they will be closely monitored for any changes in their condition. This study is currently recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with histologic confirmation of high grade glioma
• • Patients must be age \>= 18 years
• • Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol, and has been approved and amended by the MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB)
• • Patients must have Karnofsky performance status (KPS) \>= 60
• • Patients must be able to obtain an MRI scan with gadolinium contrast
• • Female patients of childbearing age must not be pregnant as determined with a serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breastfeeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Female patients who consent to participate in the study will need to use contraceptive methods for the duration of the study